BridgeBio Pharma BBIO Reportable Segment — Interest Expense, Nonoperating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's reportable segment — interest expense, nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's reportable segment — interest expense, nonoperating?
- BridgeBio Pharma (BBIO) reported reportable segment — interest expense, nonoperating of $12.94M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — interest expense, nonoperating changed year-over-year?
- BridgeBio Pharma's reportable segment — interest expense, nonoperating decreased by 28.6% year-over-year, from $18.12M to $12.94M.
- What does reportable segment — interest expense, nonoperating mean?
- The cost of servicing debt obligations.
- How do you interpret reportable segment — interest expense, nonoperating?
- Higher expenses indicate increased leverage and higher financial risk.
- How does reportable segment — interest expense, nonoperating compare across companies?
- Standard interest expense reporting.